FUS P525L

# Research Brief: FUS P525L Variant ## Pathogenic Mechanisms The FUS P525L mutation, located within the nuclear localization signal (NLS) at the critical PY-motif (Pro525-Tyr526), disrupts essential nuclear import machinery by weakening binding affinity to karyopherin β2 (Kapβ2/Transportin-1). Molecular dynamics simulations demonstrate that the proline-to-leucine substitution causes loss of native hydrophobic contacts with Kapβ2 residues (L419, I457, W460), shifting the protein to an open conformation that exposes hydrophilic surfaces and eliminates spring-like motion at the binding interface. This structural destabilization results in cytoplasmic mislocalization of FUS, where the protein undergoes aberrant self-aggregation and forms persistent stress granule-like inclusions. The mislocalized FUS exhibits toxic gain-of-function properties, including altered interactions with chromatin-binding partners (H1.2, PARP1), enhanced PARylation, mitochondrial dysfunction, and reshaping of stress granule composition toward AU-rich, poorly structured neurodegenerative-associated RNAs. These molecular cascades converge on disruption of normal RNA binding and membraneless organelle assembly functions—core biological processes annotated for FUS through GO terms—ultimately driving motor neuron degeneration. ## Clinical Significance FUS P525L is strongly associated with **juvenile-onset amyotrophic lateral sclerosis (jALS)**, characterized by aggressive disease progression, onset before age 25, and full motor penetrance. The variant frequently arises de novo and represents one of the most severe FUS mutations in terms of phenotypic impact. Approximately 30% of P525L carriers present with comorbid intellectual disability due to oligogenic contributions from variants in ID-related genes (SCUBE2, CARD11), suggesting broader neurodevelopmental consequences beyond motor neuron pathology. The completion of first baseline data collection for P525L carriers marks a critical milestone in natural history studies, establishing systematic clinical, cognitive, and biomarker measurements that will enable identification of presymptomatic disease signatures and predictive models for symptom onset timing. This foundational dataset provides essential reference ranges for longitudinal monitoring and early intervention trials. ## Therapeutic Landscape The therapeutic development landscape for FUS P525L remains in early stages, with current efforts focused on foundational research rather than variant-specific interventions. The primary aggregation mechanism—cytoplasmic mislocalization driving stress granule persistence—suggests several therapeutic angles: restoration of nuclear import through Kapβ2 binding enhancement, prevention of cytoplasmic aggregation, or modulation of stress granule dynamics. The disrupted PY-motif represents a challenging target for small molecule therapeutics due to the loss-of-function nature of the mutation. No peptide inhibitors have been specifically developed for P525L, though strategies targeting FUS-PARP1 interactions or PARylation-dependent aggregation pathways may offer promise. The availability of AlphaFold structural data (2 structures) provides computational frameworks for structure-based drug design, particularly for stabilizing the FUS-Kapβ2 interface or preventing pathological protein-protein interactions involving known FUS interactors (TARDBP, TAF15, SAFB, RBMX). ## Research Directions Critical knowledge gaps include: (1) mechanistic understanding of how oligogenic variants contribute to intellectual disability phenotypes in P525L carriers; (2) identification of early biomarkers that predict conversion from presymptomatic to symptomatic disease states; (3) validation of stress granule proteome alterations as therapeutic targets; and (4) development of nuclear import restoration strategies specifically addressing the weakened Kapβ2 binding. The baseline clinical dataset provides infrastructure for genotype-phenotype correlation studies that could stratify P525L carriers by disease severity risk. Structural biology efforts should focus on characterizing the mutant FUS-Kapβ2 complex to identify stabilizing compounds. Additionally, investigating the reshaping of stress granule RNA composition toward AU-rich transcripts may reveal RNA-based therapeutic opportunities. Cross-variant synthesis with other FUS NLS mutations could identify shared therapeutic targets while elucidating mutation-specific pathogenic mechanisms that drive the particularly aggressive jALS phenotype associated with P525L.